List of Tables
AstraZeneca Plc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 22
AstraZeneca Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 23
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 24
AstraZeneca Plc, Deals By Therapy Area, 2011 to YTD 2017 25
AstraZeneca Plc, Medical Devices Deals, 2011 to YTD 2017 27
AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 28
AstraZeneca Acquires Core Respiratory Business from Takeda Pharmaceutical for USD575 Million 50
AstraZeneca to Acquire Rights to OX-CLI Project from Orexo 51
AstraZeneca Acquires US Biologics Manufacturing Facility from Amgen 52
AstraZeneca Acquires Respiratory Drug Business from Actavis in US and Canada 53
Astrazeneca Acquires Almirall Respiratory Franchise for up to USD2.1 billion 54
MedImmune Acquires Patent Rights and Technologies from Allozyne 56
AstraZeneca Exercises Option to Acquire Interest in Proton Pump Inhibitor Products from Merck 57
AstraZeneca Acquires CDK9 Inhibitor Program From Probiodrug 59
Horizon Pharma Acquires US Rights To Vimovo From Pozen 61
AstraZeneca And BMS Acquires Exenatide From Eli Lilly Japan 62
AstraZeneca Acquires Neuroscience Assets From Link Medicine 63
Albireo to Raise USD10 Million in Venture Financing 64
G1 Therapeutics Raises USD47 Million in Series C Financing 65
Rani Therapeutics Raises Funds in Financing 67
PhaseBio Pharma Raises USD40 Million in Series C Venture Financing 69
G1 Therapeutics Raises USD33 Million in Series B Financing 71
Moderna Therapeutics Raises USD450 Million in Venture Financing 73
Definiens Raises USD20.3 Million in Venture Financing Round 75
ZS Pharma Raises US$55 Million In Series D Financing 76
Catabasis Pharma Raises US$32.4 Million In Series B Financing 78
G1 Therapeutics Raises US$12.5 Million In Series A Financing 80
Inotek Pharma Raises US$21 Million In Venture Financing 81
AesRx Raises US$1.35 Million In Venture Financing 83
Acerta Pharma Raises Funds through Series A Venture Financing 84
Omthera Pharma Raises US$17.6 Million In Venture Financing 85
Applied Genetic Technologies Raises US$37.5 Million In Series B Financing 86
Pearl Therapeutics Secures USD23.27 Million in Venture Funding 88
Pearl Therapeutics Raises US$65 Million In Series D Financing 89
Ambit Biosciences Raises US$25 Million In First Tranche Of Venture Financing 91
ZS Pharma Raises US$46 Million In Series C Financing 93
Definiens Raises US$13 Million In Venture Financing 94
Coferon Raises US$12 Million In Series B Venture Financing Round 95
ZS Pharma Secures Additional US$1 Million In Series A Financing 96
ADC Therapeutics To Raise US$50 Million In Venture Financing 97
Omthera Pharma Secures Additional US$5.1 Million In Series B Financing 99
Catabasis Pharma Secures US$8 Million In Extended Series A Financing 100
NeuProtect Secures Second Venture Financing Round 102
Inotek Pharma Raises An Additional US$9.35 Million In Venture Financing 103
Ambit Biosciences Secures US$30 Million In Series D-2 Financing 105
ADC Therapeutics Raises USD200 Million in Private Placement of Shares 107
MedImmune Enters Into Licensing Agreement With Progenics Pharma For Clostridium Difficile Preclinical Program 108
G1 Therapeutics Enters into Collaboration Agreement with AstraZeneca 109
AstraZeneca Forms Joint Venture with SDIC Fund 110
AstraZeneca Enters into Agreement with University of Michigan 111
AstraZeneca and MedImmune Expands Agreement with Incyte 112
Sawai Pharmaceutical Enters Into Manufacturing And Marketing Agreement with AstraZeneca 113
Roivant Sciences Enters into Development Partnership with AstraZeneca 114
NewLink Genetics Enters into Agreement with AstraZeneca 115
AstraZeneca and Takeda Pharma Enter into Co-Development Agreement 116
BERG Enters into Research Partnership with AstraZeneca 117
Ethris Enters into Research Agreement with Astrazeneca and MedImmune 118
Champions Oncology Enters into Agreement with AstraZeneca 119
AstraZeneca Enters into Agreement with Merck 120
MedImmune Enters into Agreement with Washington University School of Medicine 121
Pieris Pharma Enters into Development Agreement with AstraZeneca 122
Eleven Biotherapeutics Enters into R&D Agreement with National Cancer Institute and Astrazeneca 123
Genomic Vision Enters into Partnership with AstraZeneca 124
Kyowa Hakko Kirin Enters into Agreement with AstraZeneca 125
Sanofi Enters into Co-Development Agreement with MedImmune 126
APT Therapeutics Enters into Agreement with AstraZeneca 127
AstraZeneca Enters into Co-Development Agreement with Eli Lilly for MEDI1814 128
Bicycle Therapeutics Enters into Agreement with AstraZeneca 129
MedImmune Enters into Co-Development Agreement with Abpro 130
AstraZeneca Enters into Co-Marketing Agreement with Aspen 131
Asthma, AstraZeneca, British Lung Foundation and MRC Technology Enter into Research Agreement 132
Centre for Drug Research and Development Partners with AstraZeneca 133
Foundation Medicine Enters into Agreement with AstraZeneca 134
MedImmune Enters into Agreement with Genisphere 135
Esteve Enters into Agreement with AstraZeneca 136
Foundation Medicine Partners with AstraZeneca 137
Daewoong Pharma Enters into Agreement with AstraZeneca 138
Sun Pharma Enters into Co-Marketing Agreement with AstraZenceca Pharma for Dapagliflozin 139
Lipigon Pharma Enters into Research Agreement with AstraZeneca 140
PROOF Centre Partners with AstraZeneca 141
AstraZeneca and MedImmune Enter into Agreement with University of Michigan and Eli Lilly 142
Allergan Enters into Co-Development Agreement with AstraZeneca 143
Cepheid, MedImmune and Combacte Enter into Agreement 144
Incyte Enters into Agreement with AstraZeneca 145
AstraZeneca Enters into Co-Development Agreement with Moderna Therapeutics 146
Rani Therapeutics Enters into Agreement with MedImmune 147
AstraZeneca Enters into Agreement with WuXi AppTec 148
AstraZeneca Enters into Agreement with Wallenberg Centre for Protein Research 149
Cerulean Pharma and AstraZeneca Enter into Research Agreement with National Cancer Institute 150
Igenica Biotherapeutics Enters into Research Agreement with MedImmune 151
MedImmune, GlaxoSmithKline and Vanderbilt University Enter into Agreement 152
Hutchison MediPharma Enters into Agreement with AstraZeneca 153
Alvogen Enters into Marketing Agreement with AstraZeneca 154
AstraZeneca Enters into Co-Development Agreement with University of Manchestery 155
Peregrine Pharma Expands its Agreement with AstraZeneca 156
Fujifilm Kyowa Kirin Biologics to Form Joint Venture with AstraZeneca 157
MedImmune Enters into Research Agreement with University of Sheffield 158
AstraZeneca Enters into Option Agreement with Kyowa Hakko Kirin 159
AstraZeneca Enters into Research Agreement with Adelaide Research & Innovation 160
AstraZeneca Enters into Research Agreement with Inserm 161
Vall d'Hebron Institute of Oncology Enters into Agreement with AstraZeneca 162
AstraZeneca Forms Joint Venture with Salhi and Hasnaoui 163
Sun Pharma Enters into Distribution Agreement with Astrazeneca Pharma 164
AstraZeneca Expands Research Agreement with Eli Lilly 165
Dr Reddy's Labs Enters into Distribution Agreement with Astrazeneca Pharma 166
AstraZeneca Enters into Co-Development Agreement with Abbott Labs 167
AstraZeneca Enters into Research Agreement with Sutter Health 168
Celgene Enters into Co-Development Agreement with MedImmune 169
Innate Pharma Enters into Co-Development Agreement with AstraZeneca for Immuno-Oncology 170
MedImmune Enters into Agreement with Juno Therapeutics 171
Bina Technologies Enters into Agreement with AstraZeneca 172
AstraZeneca Expands Drug Discovery Agreement with Lead Discovery Center 173
PatientsLikeMe Enters into Research Agreement with AstraZeneca 174
AstraZeneca Enters into Research Agreement with Harvard Stem Cell Institute 175
AstraZeneca Enters into Commercialization Agreement with Daiichi Sankyo for Movantik 176
MedImmune Enters into Research Agreement with Joslin Diabetes Center 177
Orca Pharma Enters into Development Agreement with AstraZeneca 178
MedImmune Enters into Research Agreement with University of Manchester 179
MedImmune Enters into Research Agreement with COEBP 180
AstraZeneca Enters into Research Agreement with Broad Institute and Whitehead Institute 181
AstraZeneca Enters into Research Agreement with Wellcome Trust Sanger Institute 182
AstraZeneca Enters into Research Agreement with Thermo Fisher Scientific 183
AstraZeneca Enters into Research Agreement with Innovative Genomics Initiative 184
Hutchison Sinopharm Pharma Enters into Distribution Agreement with AstraZeneca for Seroquel 185
AstraZeneca Enters into Research Agreement with University of Texas MD Anderson Cancer Center 186
MedImmune Enters into Co-Development Agreement with National Cancer Institute 187
Molplex Enters into Research Collaboration with AstraZeneca 188
Tetragenetics Enters into Agreement with MedImmune for Drug Discovery Program 189
AstraZeneca Partners with Biognosys 190
Lipigon Pharma Enters into Research Collaboration Agreement with AstraZeneca 191
AstraZeneca Expands Co-Development Agreement with Isis Pharma 192
AstraZeneca Forms Joint Venture with University of Manchester 193
AstraZeneca and MedImmune Enter into R&D Agreement with University of Cambridge 194
Cancer Research UK Forms Joint Venture with MedImmune 196
AstraZeneca Enters into Co-Development Agreement with Eli Lilly for AZD3293 197
Astrazeneca Enters into Research Agreement with Redx Pharma 198
AstraZeneca Enters into Research Agreement with Mitsubishi Tanabe 199
AstraZeneca Enters into Co-Development Agreement with Qiagen 200
AstraZeneca Enters into Co-Development Agreement with Roche 201
Advaxis Enters into Agreement with MedImmune 202
AstraZeneca Enters into Joint Venture Agreement with Max Planck Institute of Molecular Physiology 203
AstraZeneca Extends Collaboration with MRC Technology 204
AstraZeneca Extends its Co-Development Agreement with MRC 205
AstraZeneca Enters into Co-Development Agreement with Academic Drug Discovery Consortium 206
Gustave Roussy Enters into Research Agreement with AstraZeneca 207
AstraZeneca Forms Joint Venture with Samsung Biologics 208
AstraZeneca Enters Into Drug Discovery Agreement With Medical Research Council 209
AstraZeneca Enters Into Co-Development Agreement With Shenzhen University 210
MedImmune Enters Research Agreement With University of Texas MD Anderson 211
MedImmune Enters Into Research Agreement With Cambridge University 212
Biolojic Design Enters into Partnership with MedImmune 213
AstraZeneca Enters into Research Agreement with Shanghai Institutes for Biological Sciences 214
MedImmune Enters Into Research Agreement With Johns Hopkins University 215
AstraZeneca Enters Into Agreement With Bristol-Myers To Commercialize Dapagliflozin In Japan 216
AstraZeneca Enters Into Co-Promotion Agreement With Ono Pharma For Dapagliflozin 217
AstraZeneca Enters Into Research Agreement With Lieber Institute 218
A*STAR Enters Into Co-Development Agreement With AstraZeneca For Antimicrobial Drugs 219
Taris BioMedical Enters Into Research Agreement With AstraZeneca 221
MedImmune Enters Into Co-Development Agreement With ADC Therapeutics 222
AstraZeneca Enters Into Co-Promotion Agreement With Janssen For Abiraterone Acetate 223
X-Chem Extends Drug Discovery Agreement With AstraZeneca 224
Labcyte Enters Into Agreement With AstraZeneca To Develop Acoustic Sample Handling Technology 225
AstraZeneca Enters Into Drug Discovery Agreement With Hadasit 226
AstraZeneca Enters Into Co-Development Agreement With FibroGen For FG-4592 227
Biosortia Pharma Enters into Research Agreement with AstraZeneca 228
Sarah Cannon Research Institute And AstraZeneca Enter Into Agreement For Personalized Medicine 229
AstraZeneca, Roche And MedChemica Enter Into Agreement To Accelerate Drug Development 230
MedImmune Enters Into Co-Development Agreement With NGM Biopharma 231
Cancer Research Technology, University of Manchester And AstraZeneca Enters Into Agreement To Develop Cancer Drugs 232
NeoMed Enters Into Research Agreement With AstraZeneca 233
National Institute on Drug Abuse and AstraZeneca Enter into Partnership 234
Alchemia Enters Into Drug Discovery Agreement With AstraZeneca 235
Bind Therapeutics Enters Into Co-Development Agreement With AstraZeneca For Accurin 236
AstraZeneca Enters Into Co-Development Agreement With Moderna Therapeutics For Messenger RNA Therapeutics 237
Cancer Research Technology And AstraZeneca Extend Co-Development Agreement For Anti-Cancer Drugs 239
AstraZeneca Enters Into Co-Development Agreement With Petrov Institute 240
AstraZeneca Enters Into Drug Discovery Agreement With Lead Discovery Center 241
Orexo Enters Into Research Agreement With AstraZeneca For OX-CLI Program 242
Serina Therapeutics Enters into Co-Development Agreement with AstraZeneca 243
Cellular Dynamics International Enters Into Agreement With AstraZeneca On Use Of iPSC-Derived Human Cells In Drug Discovery 244
CytImmune Sciences and AstraZeneca Enter into Research Agreement 245
AstraZeneca Enters into Agreement with LegoChem for Antibiotic-Resistant Bacterial Infections 246
Pierre Fabre Medicament Enters Into Co-Promotion Agreement With AstraZeneca For Zoladex 247
Par Pharma Enters Into Distribution Agreement With AstraZeneca For Atacand HCT 248
AstraZeneca And Pfizer Partner With Government of Quebec To Develop Research Centre 249
Foundation Medicine Enters Into Agreement With AstraZeneca For Genomic Profiling 250
PeptiDream Enters into Drug Discovery Agreement with MedImmune 251
AstraZeneca Enters Into Co-Development Agreement With Ironwood Pharma For Linaclotide 252
AstraZeneca Enters Into Co-Promotion Agreement With Ironwood Pharma For Nexium 254
Charles River Labs Expands its Agreement with AstraZeneca 255
Pharmaron Enters Into Drug Discovery Agreement With AstraZeneca 256
Medimmune Enters Into Research Agreement With Cancer Research Institute And Ludwig Institute for Cancer Research 257
AstraZeneca And Broad Institute Partner To Advance Discovery Of Antibacterial And Antiviral Agents 259
Medimmune And Wuxi Apptec Form Joint Venture To Develop Biologic MEDI5117 For Chinese Market 260
Starpharma Holdings Enters into Agreement with AstraZeneca 261
Regulus Therapeutics Enters into Collaboration Agreement with AstraZeneca 262
Knode Enters Into Co-Development Agreement With AstraZeneca 263
Assay Depot Enters Into Joint Venture Agreement With AstraZeneca 264
AstraZeneca Enters Into Co-Development Agreement With Cellworks Group 265
AstraZeneca Amends Co-Development Agreement With Merck For Nexium And Prilosec 266
X-Chem Enters Into Drug Discovery Agreement With AstraZeneca 267
AstraZeneca Aktiebog Enters into Distribution Agreement with Meiji Seika Pharma 268
AstraZeneca Enters Into Co-Promotion Agreement With The Medicines Company For Brilinta 269
AstraZeneca And Conformetrix Enter Into Co-Development Agreement 270
PolyTherics Enters Into Co-Development Agreement With Spirogen For Cancer Drug 271
Amgen Enters into Co-Development Agreement with AstraZeneca for Five Monoclonal Antibodies 272
Enlight Biosciences Enters Into Co-Development Agreement With AstraZeneca And Novo Nordisk 274
University Of Michigan Medical School Enters Into Research Agreement With MedImmune 275
AgonOx Enters Into Co-Development Agreement With MedImmune 276
AstraZeneca Extends Co-Development Agreement With Dynavax Technologies For AZD 1419 277
AstraZeneca Enters Into Co-Development Agreement With Heptares 279
AstraZeneca Enters Into Co-Promotion Agreement With Daiichi Sankyo For Denosumab 281
GlaxoSmithKline, AstraZeneca And The University Of Manchester Form Joint Venture 282
Agendia Enters Into Collaboration With AstraZeneca And The Netherlands Cancer Institute 284
Pfenex Enters Into Collaboration With MedImmune 285
Leica Microsystems Enters Into Co-Marketing Agreement With Definiens 286
MedImmune Enters Into Co-Development Agreement With Inserm Transfert 287
Advanced Cell Diagnostics Enters Into Co-Development Agreement With Definiens 288
Senectus Therapeutics Enters into Partnership with AstraZeneca 289
Sage Bionetworks Enters Into Collaboration With AstraZeneca 290
AstraZeneca Enters Into Research And Development Agreement With Galderma Pharma 291
AstraZeneca Enters Into Joint Venture With Sanofi, University Of Cambridge, EPFL, And Universities Of Pavia And Uppsala 292
AstraZeneca Enters Into Co-Development Agreement With Sarah Cannon Research Institute 294
KINAXO Biotechnologies Enters Into Collaboration With AstraZeneca 295
AstraZeneca Rumored To Merge With Amgen 296
PhaseBio Pharma Enters into Licensing Agreement with MedImmune 297
AstraZeneca Enters into Licensing Agreement with Moderna Therapeutics 298
Mereo Biopharma Enters into Licensing Agreement with AstraZeneca 299
GamaMabs Enters into Licensing Agreement with MedImmune 300
TerSera Therapeutics Enters into Licensing Agreement with AstraZeneca for Zoladex 301
Knight Therapeutics Enters into Licensing Agreement with AstraZeneca for Movantik 302
Hongkong Sansheng Medical Enters into Licensing Agreement with AstraZeneca 303
Biohaven Pharma Enters into Licensing Agreement with AstraZeneca 304
Insmed Enters into Licensing Agreement with AstraZeneca 305
Allergan Enters into Licensing Agreement with AstraZeneca 306
Ironwood Pharma Enters into Licensing Agreement with AstraZeneca 307
Grunenthal Enters into Licensing Agreement with AstraZeneca 308
Regeneron Pharma Enters into Licensing Agreement with MedImmune 309
ProStrakan Enters into Licensing Agreement with AstraZeneca for Moventig 310
China Medical System Enters into Licensing Agreement with AstraZeneca 311
Millendo Therapeutics Enters into Licensing Agreement with AstraZeneca for MLE4901 312
MedImmune Enters into Licensing Agreement with Wacker Biotech 313
Valeant Pharma Amends Licensing Agreement with AstraZeneca 314
MedImmune Enters into Licensing Agreement with 3M Drug Delivery Systems 315
Tanabe Research Labs Enters into a Licensing Agreement with MedImmune 316
Daiichi Sankyo Enters into Licensing Agreement with MedImmune for FluMist 317
MedImmune Enters into Licensing Agreement with Inovio Pharma 318
AstraZeneca to Enter into Licensing Agreement with Heptares Therapeutics for HTL-1071 319
AstraZeneca Enters into Licensing Agreement with Isis Pharma 320
Emeriti Pharma Receives Intellectual Property Rights from AstraZeneca 321
Ligand Pharma Enters Into Licensing Agreement With Omthera Pharma 322
AstraZeneca Enters Into Licensing Agreement with VIB and CD3 323
Kolltan Pharma Enters into Licensing Agreement with Spirogen 324
Isis Pharma Enters Into Licensing Agreement With AstraZeneca 325
AstraZeneca Enters Into Licensing Agreement With Pfizer For Nexium 327
Clovis Oncology Enters into Licensing Agreement with AstraZeneca 329
Impax Pharma Amends Licensing Agreement with AstraZeneca for Zomig 330
MedImmune To Enter Into Licensing Agreement With Pfizer 332
Sinovac Biotech Amends Licensing Agreement with MedImmune 333
LEO Pharma Enters into Licensing Agreement with AstraZeneca for Tralokinumab 334
LEO Pharma Enters into Licensing Agreement with AstraZeneca for Brodalumab 335
Corvidia Therapeutics Enters into Licensing Agreement with AstraZeneca 336
AstraZeneca Enters into Licensing Agreement with Starpharma 337
AstraZeneca Enters into Licensing Agreement with Eolas Therapeutics 338
MedImmune Enters into Licensing Agreement with Omnis Pharma 339
AstraZeneca Amends Research and Licensing Agreement with Dynavax 340
Shionogi Enters into Licensing Agreement with MedImmune 342
AstraZeneca Enters into Licensing Agreement with Synairgen for SNG001 343
biOasis Enters Into Licensing Agreement With Medimmune For Transcend Brain Delivery Platform 344
AstraZeneca Enters Into Licensing Agreement With FOB Synthesis 345
MedImmune And Immunocore Enter Into Licensing Agreement To Develop Cancer Therapies 346
Horizon Discovery Enters Into Licensing Agreement With AstraZeneca 348
Humabs Biomed Enters into Licensing Agreement with MedImmune 349
Biowa And Lonza Enter Into Licensing Agreement With MedImmune For Potelligent CHOK1SV 350
Evotec Enters Into Licensing Agreement With AstraZeneca For Kidney Disease Treatment 351
AstraZeneca Enters Into Licensing Agreement With X-Chem For Three Drug Discovery Programs 352
AstraZeneca Enters Into Licensing Agreement With Merck For MK-1775 353
Kolltan Pharma Enters Into Licensing Agreement With MedImmune 355
AstraZeneca Enters Into Licensing Agreement With Optibrium For StarDrop Drug Discovery Software 356
Horizon Discovery And AstraZeneca Enter Into Licensing Agreement To Develop Cancer Therapies 357
Acerta Pharma Enters into Licensing Agreement with Merck Sharp & Dohme 359
Targacept And AstraZeneca Amend Licensing Agreement For Cognitive Disorders 360
AstraZeneca Enters Into Licensing Agreement With Vanderbilt University For Neuroscience Drug Discovery 362
AstraZeneca Enters into Licensing Agreement with Vanderbilt University 363
Evotec Expands Licensing Agreement With MedImmune For Diabetes And Beta Cell Regeneration 364
Optimer Pharma Enters Into Licensing Agreement With AstraZeneca For Clostridium Difficile Infection Drug 365
Axerion Therapeutics Enters Into Licensing Agreement With MedImmune For Alzheimer’s Disease 366
AstraZeneca Amends Licensing Agreement with Hutchison MediPharma for Savolitinib 367
AstraZeneca Enters Into Collaboration And Licensing Agreement With PTC Therapeutics 369
Taj Pharma Enters Into Licensing Agreement With ASTRAZENECA Pharma For Gemcitabine HCI 370
MedImmune Enters Into Licensing Agreement With Amgen For AMG 108 371
Spirogen Enters Into Licensing Agreement With Genentech 372
ADC Therapeutics Raises USD105 Million in Private Placement of Shares 373
AstraZeneca Invests USD140 Million in Moderna Therapeutics 374
ADC Therapeutics Raises USD80 Million in Private Placement of Shares 375
ZS Pharma Prices Public Offering of Shares for USD185.7 Million 376
FibroGen to Raise USD20 Million in Private Placement of Shares 377
ZS Pharma Raises USD123 Million in IPO of Shares 379
Omthera Pharma Completes IPO For US$64 Million 381
Regulus Therapeutics Completes Private Placement Of Shares For US$25 Million 383
Ardea Biosciences Completes Public Offering Of Common Stock For US$166 Million 384
Ardea Biosciences Completes Exercise Of Underwriters’ Over-allotment Option For US$82 Million 386
PhaseBio Pharma to Raise USD8.1 Million in Second Tranche of Private Placement of Convertible Notes 388
AstraZeneca Prices Public Offering of Notes Due 2022 for USD0.25 Billion 390
AstraZeneca Prices Public Offering of 2.375% Notes Due 2022 for USD1 Billion 391
AstraZeneca Prices Public Offering of 3.125% Notes Due 2027 for USD0.75 Billion 392
PhaseBio Pharma Raises USD14.7 Million in Private Placement of Convertible Notes 393
AstraZeneca Prices Public Offering of 1.25% Notes for USD912 Million 395
AstraZeneca Prices Public Offering of 0.75% Notes for USD1 Billion 396
AstraZeneca Prices Public Offering of 0.25% Notes for USD570 Million 397
AstraZeneca Prices Public Offering of Floating Rate Notes Due 2018 for USD400 Million 398
AstraZeneca Prices Public Offering of 2.375% Notes Due 2020 for USD1.6 Billion 399
AstraZeneca Prices Public Offering of 1.75% Notes Due 2018 for USD1 Billion 400
AstraZeneca Prices Public Offering of 3.375% Notes Due 2025 for USD2 Billion 401
AstraZeneca Prices Public Offering of 4.375% Notes Due 2045 for USD1 Billion 402
AstraZeneca Prices Private Placement of 0.875% Notes Due 2021 403
AstraZeneca Completes Public Offering Of Notes Due 2042 For US$1 Billion 404
AstraZeneca Completes Public Offering Of Notes Due 2019 For US$1 Billion 405
Egis Pharma Acquires Sorbifer Rights from AstraZeneca 406
Avara Pharma Acquires Reims Manufacturing Facility from AstraZeneca 407
Aspen to Acquire Remaining Rights to Anaesthetic Portfolio from Astrazeneca 408
Grunenthal Acquires Rights to Zomic from AstraZeneca 409
Recordati Acquires Rights for Seloken from Astrazeneca 410
Pfizer to Acquire Neksium Brand from AstraZeneca 411
Circassia Pharma Acquires US Rights to Two COPD Products from AstraZeneca 412
Zydus Cadila Healthcare May Acquire 8 brands from Astrazeneca India 414
Pfizer Acquires Small Molecule Anti-Infective Business from AstraZeneca 415
Cilag Acquires Rights to Rhinocort Aqua Outside the US from Astrazeneca 417
Avara Pharma Acquires Manufacturing Facility from AstraZeneca 418
Aralez Pharma Acquires US Rights to Toprol-XL and Authorized Generic from AstraZeneca 419
China Medical System Acquires Rights to Imdur from AstraZeneca 421
Perrigo Acquires US Rights to Entocort from AstraZeneca for USD380 Million 422
Genzyme Acquires Caprelsa from AstraZeneca 423
Acturum Life Science Acquires Rights to Fractalkine Project from AstraZeneca 424
Tillotts Pharma Acquires Entocort from AstraZeneca 425
IGI Labs Acquires 18 Injectable Products from AstraZeneca for USD6.5 Million 426
Clinigen Group Acquires Ethyol from AstraZeneca 427
Acturum Development Acquires Sodertalje R&D facilities of AstraZeneca 428
BiQ Pharma Acquires Research Facility from AstraZeneca 429
Alliance Pharma Acquires Antimalarial Drug Brands From AstraZeneca UK For US$8 Million 430
AstraZeneca May Acquire Acadia Pharma 431
AstraZeneca Acquires 55% Stake in Acerta Pharma 432
AstraZeneca Acquires ZS Pharma for USD2.7 Billion 433
Actelion Plans to Acquire ZS Pharma 435
AstraZeneca May Acquire Juno Therapeutics 436
Pfizer May Increase Bid to Acquire AstraZeneca 437
MedImmune Acquires Definiens for USD150 Million 439
AstraZeneca May Acquire Ariad Pharma 440
AstraZeneca Completes Acquisition Of Remaining 20% Stake In AstraZeneca K.K. From Sumitomo Chemical For US$102 Million 442
AstraZeneca Completes Acquisition Of Remaining 50% Interest In Diabetes Joint Venture From Bristol-Myers Squibb For US$4.3 Billion 444
AstraZeneca Rumored To Acquire Forest Labs For US$15 Billion 446
MedImmune Acquires Spirogen From Auven Therapeutics For US$440 Million 447
MedImmune Completes Acquisition Of Amplimmune For Up To US$500 Million 449
AstraZeneca Completes Acquisition Of Omthera Pharmaceuticals For Up To US$443 Million 450
AstraZeneca Completes Acquisition Of Pearl Therapeutics, Respiratory Therapies Developer, For Up To US$1.15 Billion 452
Celltrion Chairman Jung Jin Seo Plans To Sell Controlling Stake In The Company 454
MedImmune Acquires AlphaCore Pharma, Cholesterol Drug Developer 456
AstraZeneca Reportedly Mulls Acquisition of Shire 457
Takeda America Completes Acquisition Of LigoCyte Pharma For US$60 Million 458
AstraZeneca Completes Sale Of Aptium Oncology For Up To US$500 Million 460
AstraZeneca Completes Acquisition Of Ardea Biosciences, Gout Drug Maker, For US$1.26 Billion 461
AstraZeneca To Acquire Remaining 10% Stake In Astrazeneca Pharma India 463
Ipsen Sells 19.31% Stake In Spirogen, Developer Of DNA Sequence-Targeted Agents 464
AstraZeneca Completes Acquisition Of Guangdong BeiKang Pharma, Generics Manufacturer 465
AstraZeneca Plc, Key Competitors 466
AstraZeneca Plc, Key Employees 467
AstraZeneca Plc, Subsidiaries 470
AstraZeneca Plc, Joint Venture 475
AstraZeneca Plc (AZN)-製薬・医療分野：企業M&A・提携分析 |
◆英語タイトル：AstraZeneca Plc (AZN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8012248
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月14日
◆ページ数：654
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：イギリス
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
【レポートの概要】
◆商品コード：DATA8012248
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月14日
◆ページ数：654
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：イギリス
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
| Single User | USD250 ⇒換算￥37,000 | 見積依頼/購入/質問フォーム |
| Site License（同一事業所内共有可） | USD500 ⇒換算￥74,000 | 見積依頼/購入/質問フォーム |
| Enterprisewide License（複数事業所内共有可） | USD750 ⇒換算￥111,000 | 見積依頼/購入/質問フォーム |
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
AstraZeneca plc (AstraZeneca) is a biopharmaceutical company that endeavors to discover, produce and commercialize a wide range of prescription drugs. It focuses on therapy areas such as respiratory; cardiovascular and metabolic disease (CVMD); and cancer, besides autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies and through distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, the UK.
AstraZeneca Plc (AZN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
【レポートの目次】
| ★海外企業調査レポート[AstraZeneca Plc (AZN)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら |
